Impact of virus preparation quality on parvovirus filter performance

Biotechnology and Bioengineering

Volumn 110, Issue 1, 2013, Pages 229-239

  Slocum, Ashley ^a   Burnham, Mike ^b   Genest, Paul ^a   Venkiteshwaran, Adith ^c   Chen, Dayue ^c   Hughes, Joseph ^b  

^a MILLIPORE CORPORATION   (United States)

^b WUXI APPTEC   (China)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Downstream processes; Dynamic light scattering; Viral clearance; Virus filter performance; Virus purity; Virus removal filters

Indexed keywords

DYNAMIC LIGHT SCATTERING; MAMMALS;

BIOPHYSICAL PROPERTIES; DOWNSTREAM PROCESS; FILTER CAPACITY; FILTER PERFORMANCE; FILTRATION TECHNOLOGIES; HYDRODYNAMIC DIAMETER; INDUSTRY STANDARDS; MANUFACTURING PROCESS; PERFORMANCE PROFILE; PROCESS STEPS; PROTEIN CONTENTS; PURITY LEVEL; QUALITY ATTRIBUTES; VIRAL CLEARANCE; VIRUS REMOVAL;

VIRUSES;

ARTICLE; FILTER; FILTRATION; HYDRODYNAMICS; NONHUMAN; PARVOVIRUS; VIRUS PARTICLE; VIRUS PURIFICATION;

MAMMALIA; PARVOVIRUS;

EID: 84869862308     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.24600     Document Type: Article

References (14)

1. Asher D, Slocum A, Bergmann K, Genest P, Katz A, Morais J, Lawrence C, Greenhalgh P. 2011. Predicting virus filtration performance with virus spike characterization. Bioprocess Int 9(3): 26-37.
2. Bolton G, Spector S, Lacasse D. 2006. Increasing the capacity of parvovirus retentive membranes: Performance of the viresolve prefilter. Biotechnol Appl Biochem 43(1): 55-63.
3. Brown A, Bechtel C, Bill J, Liu H, Liu J, McDonald D, Pai S, Radhamohan A, Renslow R, Thayer B, Yohe S, Dowd C. 2010. Increasing parvovirus filter throughput of monoclonal antibodies using ion exchange membrane adsorptive pre-filtration. Biotechnol Bioeng 106(4): 627-637.
4. Cabatingan M. 2005. Impact of virus stock quality on virus filter validation. Bioprocess Int 3(10)Suppl.: 39-43.
5. EMEA. 2008. Guideline on virus safety evaluation of biotechnological investigational medicinal products. London, UK: European Medicines Agency. Doc. Ref. EMEA/CHMP/BWP/398498/2005.
6. FDA. 1997. Points to consider in the manufacture and testing of monoclonal antibody products for human use. Rockville, MD: Food and Drug Administration.
7. Garnick RL. 2006. Experience with viral contamination in cell culture. Dev Biol Stand 88: 49-56.
8. Hongo-Hirasaki T, Yamaguchi K, Yanagida K, Hayashida H, Ide S. 2011. Effect of varying virus-spiking conditions on a virus-removal filter Planova™ 20N in a virus validation study of antibody solutions. Biotechnol Prog 27: 162-169.
9. ICH. 1998. Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin, Q5A. Geneva, Switzerland: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.
10. Khan N, Parrella J, Genest P, Colman M. 2009. Filter preconditioning enables representative scaled-down modeling of filter capacity and viral clearance by mitigating the impact of virus spike impurities. Biotechol Appl Biochem 52: 293-301.
11. Lute S, Bailey M, Combs J, Sukumar M, Brorson K. 2007. Phage passage after extended processing in small-virus-retentive filters. Biotechnol Appl Biochem 47(3): 141-151.
12. Miesegaes G, Baily M, Willkommen H, Chen Q, Roush D, Blümel J, Brorson K. 2010. Proceedings of the 2009 viral clearance symposium. Dev Biol 133: 77-91.
13. Parrella J, Wu Y, Kahn D, Genest P, RUNspike. 2009. A complementary virus filter spiking method: A solution to the problem of reduced throughput due to the addition of the virus spike. PDA J Pharm Sci Technol 63(6): 547-558.
14. PDA. 2010. Technical report no. 47. Preparation of virus spikes used for virus clearance studies.